We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
Read MoreHide Full Article
Key Takeaways
Viking Therapeutics reported a Q4 2025 loss of $1.38 per share, wider than estimates.
R&D expenses surged to $153.5M on higher clinical study and employee costs.
Viking plans to start phase III for oral VK2735 in Q3 2026, lifting shares.
Viking Therapeutics (VKTX - Free Report) reported a fourth-quarter 2025 loss of $1.38 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 32 cents per share in the year-ago quarter.
Currently, Viking Therapeutics does not have any approved products in its portfolio. It has yet to generate revenues.
More on VKTX’s Q4 Earnings
Research and development expenses amounted to $153.5 million compared with $31.0 million incurred in the year-ago period. This significant increase was primarily driven by higher costs associated with clinical studies and increased employee-related expenses.
General and administrative expenses amounted to $11.3 million, down 26% year over year, mainly due to lower costs on legal and patent services.
As of Dec. 31, 2025, Viking Therapeutics had cash and cash equivalents worth $706 million compared with $715 million as of Sept. 30, 2025.
Full-Year 2025 Results
With no marketed products, Viking Therapeutics did not record any revenues during the year.
VKTX reported a loss of $3.19 per share for the full year. In the year-ago period, management reported a loss of $1.01.
VKTX’s Pipeline Updates
Viking Therapeutics is one of the few biotech stocks with immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subcutaneous (SC) versions for treating obesity.
Last year, Viking Therapeutics started a late-stage program evaluating the SC formulation of VK2735 for adults with obesity. This program consists of two phase III studies — VANQUISH-1 and VANQUISH-2. While the VANQUISH-1 study is enrolling obese adults with at least one weight-related co-morbid condition and without type II diabetes (T2D), the VANQUISH-2 study will enroll obese or overweight adults with T2D. Viking has already completed enrolment in the VANQUISH-1 study, while the same for VANQUISH-2 is expected in the first quarter of 2026.
Alongside the earnings results, Viking announced plans to advance the oral version of VK2735 into late-stage development, which is expected to start in the third quarter of 2026. This update likely drove the jump in stock price during after-market trading yesterday, as oral options are being viewed as the next growth frontier in the obesity space.
Currently, the obesity market is dominated by Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) with their respective GLP-1 injections, Zepbound and Wegovy. Novo Nordisk recently launched an oral version of Wegovy, while an FDA decision for Eli Lilly’s oral obesity pill is due in the second quarter of 2026. VKTX’s decision to advance VK2735 oral into late-stage development places it among a handful of companies with a phase III-ready oral obesity therapy. Investors appeared to welcome this announcement, as the stock price was also rising in pre-market trading today.
In the past year, the stock has lost 3% against the industry’s nearly 19% growth.
Image Source: Zacks Investment Research
Last year, Viking Therapeutics started a new maintenance dosing study on VK2735. This study is exploring multiple regimens — monthly SC, weekly oral and daily oral dosing — to check whether the initial weight loss achieved following weekly SC dosing of the drug can be sustained. The company recently completed enrolment in this study and expects to report results in the third quarter of 2026.
VKTX also remains on track to file an investigational new drug (IND) application with the FDA in the first quarter of 2026 to advance an internally developed amylin agonist program to clinical development for treating obesity.
View the Zacks #1 Rank List
Image: Bigstock
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
Key Takeaways
Viking Therapeutics (VKTX - Free Report) reported a fourth-quarter 2025 loss of $1.38 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 32 cents per share in the year-ago quarter.
Currently, Viking Therapeutics does not have any approved products in its portfolio. It has yet to generate revenues.
More on VKTX’s Q4 Earnings
Research and development expenses amounted to $153.5 million compared with $31.0 million incurred in the year-ago period. This significant increase was primarily driven by higher costs associated with clinical studies and increased employee-related expenses.
General and administrative expenses amounted to $11.3 million, down 26% year over year, mainly due to lower costs on legal and patent services.
As of Dec. 31, 2025, Viking Therapeutics had cash and cash equivalents worth $706 million compared with $715 million as of Sept. 30, 2025.
Full-Year 2025 Results
With no marketed products, Viking Therapeutics did not record any revenues during the year.
VKTX reported a loss of $3.19 per share for the full year. In the year-ago period, management reported a loss of $1.01.
VKTX’s Pipeline Updates
Viking Therapeutics is one of the few biotech stocks with immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subcutaneous (SC) versions for treating obesity.
Last year, Viking Therapeutics started a late-stage program evaluating the SC formulation of VK2735 for adults with obesity. This program consists of two phase III studies — VANQUISH-1 and VANQUISH-2. While the VANQUISH-1 study is enrolling obese adults with at least one weight-related co-morbid condition and without type II diabetes (T2D), the VANQUISH-2 study will enroll obese or overweight adults with T2D. Viking has already completed enrolment in the VANQUISH-1 study, while the same for VANQUISH-2 is expected in the first quarter of 2026.
Alongside the earnings results, Viking announced plans to advance the oral version of VK2735 into late-stage development, which is expected to start in the third quarter of 2026. This update likely drove the jump in stock price during after-market trading yesterday, as oral options are being viewed as the next growth frontier in the obesity space.
Currently, the obesity market is dominated by Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) with their respective GLP-1 injections, Zepbound and Wegovy. Novo Nordisk recently launched an oral version of Wegovy, while an FDA decision for Eli Lilly’s oral obesity pill is due in the second quarter of 2026. VKTX’s decision to advance VK2735 oral into late-stage development places it among a handful of companies with a phase III-ready oral obesity therapy. Investors appeared to welcome this announcement, as the stock price was also rising in pre-market trading today.
In the past year, the stock has lost 3% against the industry’s nearly 19% growth.
Image Source: Zacks Investment Research
Last year, Viking Therapeutics started a new maintenance dosing study on VK2735. This study is exploring multiple regimens — monthly SC, weekly oral and daily oral dosing — to check whether the initial weight loss achieved following weekly SC dosing of the drug can be sustained. The company recently completed enrolment in this study and expects to report results in the third quarter of 2026.
VKTX also remains on track to file an investigational new drug (IND) application with the FDA in the first quarter of 2026 to advance an internally developed amylin agonist program to clinical development for treating obesity.
Viking Therapeutics, Inc. Price
Viking Therapeutics, Inc. price | Viking Therapeutics, Inc. Quote
VKTX’s Zacks Rank
Viking currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.